| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer (NCT05361174) | Iovance Biotherapeutics, Inc. | 2022-07-20 |
| Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma (NCT05303493) | Centre hospitalier de l'Université de Montréal (CHUM) | 2022-06-29 |
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) (NCT05155254) | IO Biotech | 2022-05-17 |
| Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma (NCT04688658) | John Kirkwood | 2021-10-06 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (NCT04940299) | M.D. Anderson Cancer Center | 2021-09-23 |
| Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma (NCT04967196) | Mayo Clinic | 2021-09-16 |
| Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations (NCT05103891) | Pierre Fabre Medicament | 2021-09-03 |
| Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma (NCT04527549) | ECOG-ACRIN Cancer Research Group | 2021-06-01 |
| A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment (NCT04526899) | BioNTech SE | 2021-05-19 |
| Sargramostim (GM-CSF) + PD-1 (NCT04703426) | Dana-Farber Cancer Institute | 2021-04-16 |
| CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma (NCT04698187) | Regeneron Pharmaceuticals | 2021-03-11 |
| CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (NCT04695977) | Regeneron Pharmaceuticals | 2021-02-24 |
| Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial (NCT04462406) | ECOG-ACRIN Cancer Research Group | 2021-02-09 |
| Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma (NCT04759846) | Pierre Fabre Medicament | 2021-01-21 |
| Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma (NCT04493203) | Yana Najjar | 2020-12-18 |
| A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma (NCT04625205) | BioNTech US Inc. | 2020-12-01 |
| A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC (NCT04521075) | Ella Therapeutics Ltd | 2020-11-01 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (NCT03816332) | National Cancer Institute (NCI) | 2019-11-08 |
| A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma (NCT04337931) | Apexigen America, Inc. | 2019-06-12 |
| Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy (NCT03719131) | Emory University | 2019-06-05 |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) (NCT03679767) | Incyte Corporation | 2019-01-09 |
| Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (NCT03501368) | H. Lee Moffitt Cancer Center and Research Institute | 2018-06-27 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (NCT02965716) | National Cancer Institute (NCI) | 2018-06-05 |
| Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma (NCT03033576) | National Cancer Institute (NCI) | 2017-10-23 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986) | Roswell Park Cancer Institute | 2017-07-14 |
| Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT03021460) | Mayo Clinic | 2017-01-31 |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma (NCT02910700) | M.D. Anderson Cancer Center | 2016-12-09 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866) | National Cancer Institute (NCI) | 2016-04-04 |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (NCT02224781) | National Cancer Institute (NCI) | 2015-09-08 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread (NCT02196181) | National Cancer Institute (NCI) | 2014-09-19 |
| Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma (NCT02115243) | Duke University | 2014-05-01 |
| Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (NCT01989585) | National Cancer Institute (NCI) | 2014-03-24 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707) | Mayo Clinic | 2014-02-24 |
| Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01950390) | National Cancer Institute (NCI) | 2014-01-24 |
| Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (NCT02158520) | Academic and Community Cancer Research United | 2013-10-18 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (NCT01902173) | National Cancer Institute (NCI) | 2013-10-08 |
| Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (NCT01927419) | Bristol-Myers Squibb | 2013-08-23 |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations (NCT01726738) | UNC Lineberger Comprehensive Cancer Center | 2013-04-04 |
| Ipilimumab and Imatinib Mesylate in Advanced Cancer (NCT01738139) | M.D. Anderson Cancer Center | 2013-02-19 |
| Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT01134614) | National Cancer Institute (NCI) | 2010-12-28 |
| Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma (NCT01107665) | University of California, Irvine | 2010-08-01 |